Ironwood Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 97% year-over-year LINZESS net sales growth, strong profits, and progress on pediatric and rare disease indications. Apraglutide's clinical program advanced, with a large addressable market and robust safety data. Guidance for 2026 was reiterated.
-
LINZESS is projected to deliver over $1.1 billion in U.S. net sales in 2026, supporting strong profitability and funding for apraglutide's development. Apraglutide's confirmatory Phase III trial will begin in Q2, targeting a 2029 NDA submission, with commercial launch preparations leveraging LINZESS experience.
Fiscal Year 2025
-
LINZESS achieved strong demand growth and expanded its pediatric indication, while a list price reduction and improved payer access are expected to drive over 30% net sales growth in 2026. Apraglutide advances with a pivotal Phase III trial, targeting >$700M U.S. peak sales.
-
LINZESS maintains strong growth and profitability, with increased EBITDA guidance and a focus on transitioning to OTC. Apraglutide shows promising clinical results, though a confirmatory trial is required. Strategic alternatives are under review to maximize asset value.
-
Apraglutide is prioritized as the next growth driver, with NDA submission delayed to Q3 2025 to include compelling long-term data. LINZESS faces pricing headwinds, prompting a 50% workforce reduction and a shift to a more targeted commercial model. 2025 guidance reflects these strategic changes.
Fiscal Year 2024
-
Strong 2024 results driven by LINZESS growth and disciplined expense management, with $916M net sales and robust cash flow supporting apraglutide advancement. Apraglutide’s NDA submission is underway, targeting Q3 2025 completion, while 2025 guidance anticipates high single-digit LINZESS demand growth amid pricing headwinds.
-
Debt has been reduced by $200M since the VectivBio acquisition, with further paydown planned as apraglutide launches in early 2026. LINZESS remains dominant but faces pricing headwinds, prompting a shift in contracting and promotion strategy. Apraglutide targets a validated, largely untapped market with a strong clinical profile and broad indication expected.
-
2024 guidance remains strong with stable gross-to-net and double-digit Linzess demand growth, though Medicare Part D changes pose a headwind. Apraglutide's phase 3 data is highly positive, with a U.S. launch targeted for early 2026 and a large, underserved market opportunity.
-
Linzess saw strong prescription growth but net sales declined due to Medicaid-driven pricing headwinds. Apraglutide's NDA submission is on track for Q1 2025, with positive phase 3 data. Full-year guidance is maintained, and capital structure was strengthened.
-
The company is focused on maximizing Linzess profitability through 2029, launching apraglutide for short bowel syndrome in 2026, and advancing CNP-104 for primary biliary cholangitis. Apraglutide is expected to reach $1 billion in peak sales, replacing Linzess revenue by decade's end.
-
LINZESS demand remains strong, but higher Medicaid utilization and pricing headwinds led to a downward revision of 2024 guidance. Apraglutide's NDA submission is on track for Q1 2025, with positive clinical and commercial feedback supporting its launch potential.
-
The meeting, held virtually, covered director elections, executive compensation, and auditor ratification, with all proposals approved by majority vote. No questions were raised by shareholders during the meeting or Q&A session.
-
A leading GI-focused company highlighted strong phase III results for apraglutide in short bowel syndrome, with positive physician feedback and a best-in-class profile. The US market is larger than previously estimated, and a broad label and payer access are expected. Commercial launch is planned for next year.